# Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

> **NCT02592707** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 40 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Satoreotide tetraxetan
- **OTHER:** Amino acid solution
- **OTHER:** Antiemetic

## Key facts

- **NCT ID:** NCT02592707
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-06
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Terminated (Due to small number of ongoing patients. Patients ongoing at time of termination could choose to join study D-FR-01072-004 for long term follow-up.
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02592707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02592707, "Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02592707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*